U of M and BMS announce research breakthrough

Guest Contributor
March 13, 2014

The Univ of Montreal has announced a major breakthrough in its collaboration with Bristol-Myers Squibb (BMS), New York NY. A team of scientists from BMS and the Institute of Research in Immunology and Cancer (IRIC) are launching clinical trials for a new jointly discovered small molecule drug candidate acting on a novel therapeutic agent, triggering a milestone payment from BMS (R$, September 26/13). The project was supported by U of M and IRIC in Therapeutics Discovery (IRICoR), the commercialization unit of U of M's Unit for the Discovery of Medicines....

In a related development, IRIC has received $13.9 million from the provincial Fonds de partenariat pour un Québec innovant et en santé (FPQIS) to undertake projects aimed at developing novel medicines for improving population health over the next four years. The funding is explicitly targeted at R&D in collaboration with BMS and Merck and Co Inc.


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.